Ricerc@Sapienza

Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma and many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Unfortunately, only a minority of patients have a long-term benefit, while the remaining demonstrate primary or acquired resistance. Recently, it has been demonstrated that the prevalence of programmed death-ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs) varies based on the anatomical site of metastases.

Purpose: BRAF mutations represent the main negative prognostic factor for metastatic colorectal cancer and a supposed negative predictive factor of response to standard chemotherapy. We have explored survival difference in right-sided colon cancer (RCC) patients according to BRAF mutations, with the aim to identify any predictive factors of response to targeted-based therapy. Methods: A retrospective study of RCC patients, with BRAF known mutation status, treated with chemotherapy (CT) from October 2008 to June 2019 in 5 Italian centers, was conducted.

Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting,
for example, the VEGF receptors in tumors and have
improved outcomes for patients with metastatic renal cell carcinoma
(mRCC). Immune checkpoint inhibitors (ICIs) have
also been proposed for treatment of mRCC with encouraging
results. A better understanding of the activity of immune cells in
mRCC, the immunomodulatory effects of TKIs, and the characteristics
defining patients most likely to benefit from various

Background: Treatment of pancreatic metastases (PM) from renal cell carcinoma (RCC) is still an issue between
surgeons and oncologists, in the era of target-therapy.
Methods: Data from 26 patients undergoing resection of PM and extra-PM from RCC, with R0 intention were
retrospectively analysed. No one received adjuvant chemotherapy. Patients were divided into two groups; Group A
comprehends 14 patients who developed synchronous (5) or methacronous (9) extra-PM. Group B comprehends 12
patients that developed PM only.